1. Introduction {#sec1}
===============

In recent decades, emerging concepts like targeted drug delivery, intelligent drug delivery systems (DDS) and personalised medicine have led medical sciences to a significant paradigm shift. Technology --as always-have been in service of this particular scientific revolution and among the various technological advances of 20th century, nanotechnology has been one of the most promising ones, offering a great potential to produce the "ideal drug" that is safer, more biocompatible, more specifically targeted and pharmacokinetically controllable than current conventional therapeutics; although until the day, clinical application of nano-sized therapeutics have been limited due to lack of data on their physicochemical properties as well as their exclusive in vivo behaviours, making them less predictable when compared to contemporary DDSs \[[@bib1], [@bib2], [@bib3]\].

A group of trending nano-sized DDSs are based on poly (lactic-co-glycolic acid) (PLGA), a synthetic block copolymer usually fabricated via random melt copolymerization of cyclic lactides and glycolides that are products of lactic acid and glycolic acid dehydration, in the presence of high vacuum, temperature between 160 and 190 °C and a proper catalyst. PLGA is commercially available in grades different in lactic acid-glycolic acid ratio, molecular weight, inherent viscosity and ester vs. acid end groups \[[@bib4], [@bib5], [@bib6], [@bib7], [@bib8]\]. PLGA characteristics including stability, biocompatibility, biodegradability, non-immunogenic non-toxic degradation residues, controllable molecular weight, various surface modifications potential, compatibility with numerous drugs and besides well-adjusted manufacturing process, makes the polymer a favorable candidate for designing nano-sized targeted controlled release DDSs, medical and surgical devices and tissue-engineering requirements \[[@bib4], [@bib5], [@bib7]\]. Considering such appealing characteristics, FDA and European Medicine Agency have approved PLGA for several applications \[[@bib6], [@bib7]\].

In order to bring advantages of nano-scale DDSs into the patients' bedsides, an important step is to characterise their complicated drug release phenomenon as it is far different from that of larger DDSs. It is mentioned in the literature that smaller particles may have a greater initial burst release due to their capacity of entrapment or surface absorption \[[@bib9]\]. For a single drug in an equal release medium under the same condition, drug release phenomenon (in particular, mechanism and rate) could vary among different nano-sized systems due to their physicochemical properties including shape and size of the nanoparticle, ability of water absorption (swelling) or extent and rate of degradation, chemical composition, molecular weight, solubility and crystallinity of the material that forms the nanoparticles and the same parameters for its possible degradation products; Even the drug-drug or drug-polymer interactions seem to have significant effects on drug release from such delivery systems \[[@bib10]\].

Despite f the aforesaid advantageous characteristics of PLGA-based nano-scale DDSs, its drug release phenomenon seems to be a hindrance to its widespread clinical application, as parameters that determine extent and rate of the phenomenon change through the time and make it extremely convoluted \[[@bib7], [@bib11]\]. A biphasic behavior is usually apparent in drug release of small PLGA particles. A burst release is expected at the initial phase because of non-encapsulated drug molecules attached to the surface, following drug diffusion from water-filled pores and polymeric matrix as well as drug release attributed to degradation of the matrix. Degradation is rather slow when it starts and gradually decreases polymer molecular weight and thus its solubility changes environment pH by its acidic products and under such condition degradation becomes faster in an autocatalytic way \[[@bib8], [@bib10]\].

To offer a better understanding of release phenomenon from various conventional and unconventional DDSs, different models have been used. Models are mathematical interpretations of empirical phenomena and experimental findings \[[@bib12]\]. In case of drug release, mathematical models are essential means of predicting release mechanisms, as well as over-time drug concentration in the body, which determines the biological efficacy of developed DDSs. In this regard, several models have been introduced, but none of them could act as a perfect universal model. Hence, it is crucial to choose the best model that explains the release behavior of every particular DDS most properly \[[@bib12], [@bib13]\]. This study aims to provide a comparative mathematical analysis of drug release from PLGA-based nano-scale DDSs to find a general model applicable to multi-mechanistic drug release behavior PLGA reveals.

2. Materials and method {#sec2}
=======================

Sixty data sets describing the over-time drug release of sixty distinct PLGA-based nanoformulation were extracted from forty-seven articles, several introducing more than one nanoformulation. The articles were selected by investigating a combination of the terms \"polylactic-co-glycolic acid, PLGA, nanoparticle, nanomedicine, drug delivery, kinetics of release and cumulative release\" as keywords in Google Scholar, PubMed and Scopus. It was considered that the release experiments had been done in the physiologic pH (7.4) and temperature (37 °C) (except 46th data set, where pH = 5 was mentioned for release test and 54th data where pH is not mentioned but could be inferred about seven as the medium is distilled water). [Table 1](#tbl1){ref-type="table"} reveals the name of the drug, polymeric carrier and its characteristics, surface modification and nanoparticles\' shape and size related to each analysed dataset.Table 1Drug, polymer and nanoparticle characteristics.Table 1NO. of data setDrugPolymerLactide stereo-isomeric form(Lactide: Glycolide ratio)/\[PLGA: second polymer ratio\]PLGA MW or inherent viscositySurface modificationNP shapeNP size (nm) \[analytical method\]Reference1CamptothecinPLGANM[∗](#tbl1fnlowast){ref-type="table-fn"}(50:50)0.59 dL/g-[∗∗](#tbl1fnlowastlowast){ref-type="table-fn"}sphere119 ± 37 \[SEM\]\
206 ± 32 \[DLS\]\[[@bib14]\]2DoxycyclinePLGA-PCLD, L(50:50)/\[80:20\]0.55--0.75 dL/g\
\~50 kDa-sphere230-360 \[DLS\]\[[@bib15]\]3InsulinPLGA (ISTPPLG4)NM(78:22)15.4 kDaPEG2000sphere180 ± 20 \[EM\][∗∗∗](#tbl1fnlowastlowastlowast){ref-type="table-fn"}\[[@bib16]\]4InsulinPLGA (ISTPPLG6)NM(68:32)11 kDaPEG2000sphere120 ± 20 \[EM\]\[[@bib16]\]5LansoprazolePLGANM(50:50)28 kDa-sphere219.2 ± 2.9 \[DLS\]\[[@bib17]\]6LoperamidePLGAD, L(50:50)24--38 kDa-Sphere318 ± 26 \[DLS\]\[[@bib18]\]7LoperamidePLGAD, L(50:50)24--38 kDaocta-arginineSphere328 ± 3.0 \[DLS\]\[[@bib18]\]8TacrolimusPLGANM(50:50)50--75 kDa-Sphere218 ± 51 \[DLS\]\[[@bib19]\]9TacrolimusPLGANM(50:50)50--75 kDaPEGSphere220 ± 33 \[DLS\]\[[@bib19]\]10Nitric oxidePLGA-PEID,L(50:50)71 kDa-Sphere162 ± 19 \[SEM\]\
179 ± 25 \[qNano\]\[[@bib20]\]11RheinPLGANM(50:50)15 kDa-Sphere80-210 \[DLS\]\[[@bib21]\]12VEGFPLGANM(50:50)7--17 kDa-NM203 ± 9 \[DLS\]\[[@bib22]\]13CalcitriolPLGAD,L(50:50)24--38 kDa-Sphere186 ± 3 \[DLS\]\[[@bib23]\]14CerebrolysinPLGAD, L(50:50)0.38 dl/g-Sphere to collapsed reservoir systems200 \[DLS\]\[[@bib24]\]15Carboplatin (alone)PLGA~17K~-PEG~3K~D, LNM17 kDa-NM116.3 ± 3.5 \[DLS\]\[[@bib25]\]16Carboplatin (co-encapsulated with Paclitaxel)PLGA-PEGD, LNM17 kDa-NM125.1 ± 3.9 \[DLS\]\[[@bib25]\]17Paclitaxel (alone)PLGA-PEGD, LNM17 kDa-NM88.2 ± 2.7 \[DLS\]\[[@bib25]\]18Paclitaxel (co-encapsulated with Carboplatin)PLGA-PEGD, LNM17 kDa-NM125.1 ± 3.9 \[DLS\]\[[@bib25]\]1918-β-glycyrrhetinic acidPLGAD, L(50:50)48 kDa-Sphere184 ± 25 \[DLS\]\[[@bib26]\]20Etoposide (co-encapsulated with Paclitaxel)PLGANM(50:50)15 kDaPEGSphere70 ± 4.5 \[TEM\]\
100 ± 3.68 \[DLS\]\[[@bib27]\]21DopaminePLGAD, L(50:50)30--60 kDa-Sphere119.7 ± 2.69 \[DLS\]\[[@bib28]\]22Cyclosporine APLGANM(50:50)NMPEG- liver targeting peptideNM229 \[DLS\]\[[@bib29]\]23Dnase IPLGANMNM58.8 kDa-sphere257 ± 2.83 \[DLS\]\[[@bib30]\]24FlutamidePLGAD, LNMNMmethoxy polyethene glycol 5000non-spherical133.46 ± 0.87 \[DLS\]\[[@bib31]\]25Clozapine (co-encapsulated with Risperidone)PLGA (LMW)D, L(50:50)20 kDa\
0.2 dl/g-sphere248.48 ± 11.71, 261.45 ± 12.86, 331.27 ± 19.31 \[DLS\]\[[@bib32]\]26Risperidone (co-encapsulated with Clozapine)PLGA (LMW)D, L(50:50)20 kDa\
0.2 dl/g-sphere248.48 ± 11.71, 261.45 ± 12.86, 331.27 ± 19.31 \[DLS\]\[[@bib32]\]27NetilmicinPLGAD, L(50:50)17 kDa-sphere140.83 ± 2.4 \[DLS\]\[[@bib33]\]28PerphenazinePLGA (0.8%w/v)D, L(50:50)54--69 kDa-sphere340.5 ± 17.8 \[DLS\]\[[@bib34]\]29PerphenazinePLGA (1.3%w/v)D, L(50:50)54--69 kDa-sphere382.5 ± 36.5 \[DLS\]\[[@bib34]\]30PerphenazinePLGA (1.6%w/v)D, L(50:50)54--69 kDa-sphere376.6 ± 28.6 \[DLS\]\[[@bib34]\]31CurcuminPLGA-PEGD, LNMNM-sphere70-300 \[SEM\]\[[@bib35]\]32CisplatinPLGAD,L(50:50)35--40 kDa-sphere197 ± 16 \[TEM\]\
195.35 ± 2 \[DLS\]\[[@bib36]\]33Topotecan (co-encapsulated with Tamoxifen)PLGAD,L(50:50)45 kDa\
0.4 dl/g-sphere151.2 ± 14.6 \[DLS\]\[[@bib37]\]34Tamoxifen (co-encapsulated with Topotecan)PLGAD,L(50:50)0.4 dl/g-sphere151.2 ± 14.6 \[DLS\]\[[@bib37]\]35EvodiaminePLGANM(50:50)30--60 kDa-sphere157.36 ± 1.7 \[DLS\]\[[@bib38]\]36ThienorphinePLGAD,L(50:50)15 kDa-sphere118.5 ± 13 \[DLS\]\[[@bib39]\]37ThienorphinePLGAD,L(50:50)15 kDaChitosan coat (MW \> 250 kDa)sphere121.1 ± 10 \[DLS\]\[[@bib39]\]38FlavopiridolPLGANM(50:50)NM-NMNM\[[@bib40]\]39GemcitabinePLGAD,L(50,50)0.2 dl/g-sphere100-150 \[DLS\]\[[@bib41]\]40ASC-J9PLGANM(50:50)45--60 kDa\
0.59 dl/g-sphere145.6 ± 22 \[DLS\]\[[@bib42]\]41Trans-resveratrolPLGANM(50:50)14.5 kDa\
0.53 dl/g-sphere90.35 ± 1.2--366.47 ± 2.6 \[DLS\]\[[@bib43]\]42FelodipinePLGAD,L(50:50)NM-sphere161.3 ± 2.231 \[DLS\]\[[@bib44]\]43EmtricitabinePLGAD,L(50:50)14.5 kDa\
0.53 dl/g-NM180 \[DLS\]\[[@bib45]\]44ZidovudinePLGANM(50:50)7--17 kDaTween80sphere56-93 \[PCM\][∗∗∗∗](#tbl1fnlowastlowastlowastlowast){ref-type="table-fn"}\[[@bib46]\]45RapamycinPLGAD,L(50,50)40--75 kDaPVA (average 95 kDa)NM265 \[DLS\]\[[@bib47]\]46TemazolamidePLGAD(50:50)NM-NM150-160 \[DLS\]\[[@bib48]\]47SildenafilPLGAD,L(50:50)24--38 kDa-sphere240-316 \[DSL\]\[[@bib49]\]48*Caryota mitis* ProfilinPLGANM(50:50)24--38 kDa-NM180 \[DLS\]\[[@bib50]\]49PaclitaxelPLGAD, L(50:50)10.5 kDasphere150 ± 6.2 \[DLS\]\[[@bib51]\]50MethotrexatePLGANM(50:50)12 kDa\
0.16--0.24 dl/g-sphere258 ± 10 \[DLS\]\[[@bib52]\]51MethotrexatePLGA-PEGNM(50:50)12 kDa\
0.16--0.24 dl/g-sphere182 ± 14 \[DLS\]\[[@bib52]\]52DocetaxelPLGAD, L(50:50)24--38 kDa-sphere130-150 \[DLS\]\[[@bib53]\]53AnastrozolePLGAD, L(50:50)0.2 dl/g-sphere\<200 \[DLS\]\[[@bib54]\]54IbuprofenPLGAD, L(50:50)30 kDa-NMNM\[[@bib55]\]55CytarabinePLGAD, L(50:50)0.22 dl/g-NM125 ± 2.5 \[DLS\]\[[@bib56]\]56LevofloxacinPLGAD, L(50,50)7--17 kDa-sphere268 ± 18 \[DLS\]\[[@bib57]\]57CurcuminPLGAD, L(50:50)NM-sphere129.7 ± 9.6 \[DLS\]\[[@bib58]\]58CurcuminPLGAD, L(75:25)NM-sphere191.1 ± 9.8 \[DLS\]\[[@bib58]\]59CamptothecinPLGANM(50:50)0.58 dl/g-sphere158 ± 62 \[SEM\]\[[@bib59]\]60CarvacrolPLGAD, L(50:50)0.15--0.25 dl/g-sphere209.8 ± 7.2 \[DLS\]\[[@bib60]\][^1][^2][^3][^4]

Eight conventional release models including zero order, first order, Higuchi, Hixson-Crowell, square root of mass, three-second root of mass, Weibull and Korsmeyer-Peppas, as well as the second degree polynomial model were fitted to each of 60 data sets and analysis of regression was performed in each case. The linear regression indices including slope, intercept, regression coefficient, mean of square (MS) residual, sum square of residuals (SSR) and sum square of total variation (SST) were calculated using Microsoft Excel 2011, for all datasets as well as percent of error ([equation1](#fd1){ref-type="disp-formula"}). [Table 2](#tbl2){ref-type="table"} shows the results in brief.Table 2Release media, regression and statistical analysis for referenced formulations.Table 2NO. of data setRelease mediumTime range (days)Weiball SS residualWeiball SS totalWeiball MS residualWeibull AICWeiball slopeWeiball interceptWeiball R2Weiball EKors-meyer-Peppas mReference1PBS20.023.233.23-30.160.48-0.370.991.670.20\[[@bib14]\]2PBS150.034.530.00-71.710.44-1.750.991.860.26\[[@bib15]\]3PBS1.250.165.440.04-19.251.19-2.860.978.640.66\[[@bib16]\]4PBS1.251.037.490.20-12.751.13-3.180.8618.270.67\[[@bib16]\]5PBS10.199.050.03-27.280.86-2.190.989.50.71\[[@bib17]\]6PBS30.423.880.08-15.690.571.060.8911.080.26\[[@bib18]\]7PBS30.120.920.02-25.900.27-0.290.873.350.11\[[@bib18]\]8Not mentioned160.2915.840.02-58.080.81-4.210.987.850.63\[[@bib19]\]9Not mentioned160.4916.310.04-46.250.82-4.190.979.970.63\[[@bib19]\]10DPBS60.1210.740.01-40.700.66-2.510.996.530.50\[[@bib20]\]11PBS+ 20% ethanol10.1510.110.01-47.670.80-1.510.985.370.56\[[@bib21]\]12PBS300.102.530.01-51.490.36-1.050.985.370.26\[[@bib22]\]13PBS70.174.570.03-20.870.72-2.960.968.180.52\[[@bib23]\]14PBS10.365.710.04-36.310.37-0.540.949.450.24\[[@bib24]\]15PBS30.064.210.01-27.980.70-2.690.994.790.50\[[@bib25]\]16PBS30.146.830.03-24.810.89-3.520.9810.10.68\[[@bib25]\]17PBS30.013.470.00-34.520.76-2.561.001.80.51\[[@bib25]\]18PBS30.043.790.01-24.650.79-2.800.993.980.56\[[@bib25]\]19PBS30.1312.260.00-105.790.57-1.500.992.60.33\[[@bib26]\]20PBS51.3324.620.17-22.801.06-4.550.9523.360.86\[[@bib27]\]21PBS60.072.400.00-77.490.26-1.300.973.910.20\[[@bib28]\]22PBS30.030.280.01-19.800.25-0.910.894.420.16\[[@bib29]\]23PBS (SDS + sodium azide as preservative)140.041.940.01-35.470.21-0.720.984.130.13\[[@bib30]\]24PBS70.127.080.02-30.611.08-4.450.986.780.67\[[@bib31]\]25PBS100.135.910.02-36.291.09-5.380.986.050.80\[[@bib32]\]26PBS100.186.720.02-34.941.16-5.740.977.520.86\[[@bib32]\]27PBS100.1616.740.01-70.000.49-2.600.995.850.41\[[@bib33]\]28PBS40.686.800.07-22.940.45-0.940.9011.10.28\[[@bib34]\]29PBS40.1711.410.02-38.350.61-1.740.985.360.42\[[@bib34]\]30PBS40.1611.890.02-40.400.62-1.970.996.960.46\[[@bib34]\]31Phosphate-buffered solution100.4412.750.04-32.230.71-3.470.962.020.55\[[@bib35]\]32PBS140.202.710.02-43.860.18-0.650.935.540.11\[[@bib36]\]33Phosphate buffer30.023.160.00-41.210.40-1.180.992.980.28\[[@bib37]\]34Phosphate buffer30.033.010.00-40.730.39-1.430.9940.30\[[@bib37]\]35PBS7.50.429.370.04-37.260.60-2.830.9512.190.49\[[@bib38]\]36PBS0.50.012.550.00-48.080.53-0.851.001.570.36\[[@bib39]\]37PBS0.50.025.140.00-44.310.76-1.491.003.570.57\[[@bib39]\]38PBS30.2112.720.03-26.171.08-3.800.989.410.82\[[@bib40]\]39PBS50.259.530.03-38.660.59-2.010.978.330.41\[[@bib41]\]40PBS100.136.240.02-30.230.53-1.140.985.240.32\[[@bib42]\]41PBS120.096.000.01-53.690.97-4.620.982.740.60\[[@bib43]\]42PBS (1% SLS)60.294.530.04-26.500.91-3.550.947.890.50\[[@bib44]\]43PBS150.546.990.04-39.810.87-4.640.929.720.59\[[@bib45]\]44PBS + poloxamer 4070.50.148.910.02-48.290.74-1.220.986.410.56\[[@bib46]\]45PBS (tween 80)300.775.160.05-37.800.52-2.830.8511.420.33\[[@bib47]\]46Sodium acetate buffer (pH = 5)50.092.450.01-34.060.36-1.300.964.420.23\[[@bib48]\]47PBS0.50.454.450.09-16.730.67-1.450.9016.920.52\[[@bib49]\]48PBS140.076.560.00-75.680.47-2.530.994.310.36\[[@bib50]\]49PBS40.545.010.13-13.520.52-1.760.8920.570.40\[[@bib51]\]50PBS0.50.407.100.07-22.290.85-0.970.948.60.49\[[@bib52]\]51PBS0.50.157.610.02-28.860.90-1.510.987.680.64\[[@bib52]\]52PBS (1% tween 80)70.4310.750.04-30.060.60-1.860.969.480.39\[[@bib53]\]53PBS110.577.590.04-41.620.32-1.830.9212.990.25\[[@bib54]\]54Distilled water0.10.171.280.06-16.240.830.490.864.380.26\[[@bib55]\]55PBS10.035.310.01-33.400.69-0.920.994.120.40\[[@bib56]\]56PBS50.101.080.02-23.100.38-1.760.916.360.26\[[@bib57]\]57PBS70.9611.000.10-25.820.72-2.600.9114.580.47\[[@bib58]\]58PBS70.175.020.02-44.970.50-2.060.976.660.35\[[@bib58]\]59PBS210.623.210.15-8.570.61-2.690.8116.930.21\[[@bib59]\]60PBS10.216.480.04-25.720.77-0.950.966.660.44\[[@bib60]\]

Overall error ([equation 2](#fd2){ref-type="disp-formula"}) and numbers of error bellow 5, 10, 15 and 20 percent ([equation 3](#fd3){ref-type="disp-formula"}) for each model also stipulated in [Table 3](#tbl3){ref-type="table"} as well as the name of the models and their equations. Akaike information criterion (AIC) that is a measure of fitting excellence was also calculated ([equation4](#fd4){ref-type="disp-formula"}) for each data set, and their average was reported for each model. In Eqs. [(1)](#fd1){ref-type="disp-formula"}, [(2)](#fd2){ref-type="disp-formula"}, [(3)](#fd3){ref-type="disp-formula"}, and [(4)](#fd4){ref-type="disp-formula"}, f~cal~ and f~obs~ stand for the model parameter that is obtained from the regression equation and the cumulative release curve of each article. N is the number of measuring points and p is the number of model\'s parameters.$$E = \left( 100/N \right)\sum\limits_{i = 1}^{N}\left( {f_{cal}i - \ f_{obs}i} \right)/f_{obs}i$$$$OE = \sum\limits_{i = 1}^{N}E_{i}/N$$$$NE_{i} = \left( 100 \times \ n_{i} \right)/N$$$$AIC = N \times \left\lbrack {\sum\limits_{i = 1}^{N}\left( {f_{cal}i - f_{obs}i} \right)^{2}} \right\rbrack + 2 \times p$$Table 3Mathematical models, equations and precision determinants \[[@bib13], [@bib62]\].Table 3No.Model nameEquationMean AICMean OENE\< 5%NE\< 10%NE\< 15%NE\< 20%1Zero order$f = K.t$-22.2523.403.3316.6733.3356.672First order$\ln\left( {1 - f} \right) = \  - K.t$-26.5822.801.6726.6753.33603Higuchi$f = K.t^{\frac{1}{2}}$-30.3514.668.33506576.674Hixson-Crowell$1 - \left( {1 - f} \right)^{\frac{1}{3}} = - K.t$-25.4721.86523.3351.6756.675Square root of mass$1 - \left( {1 - f} \right)^{\frac{1}{2}} = - K.t$-24.5622.253.3316.6748.3358.336Three second- root of mass$1 - \left( {1 - f} \right)^{\frac{2}{3}} = - K.t$-23.7223.02516.6740557Weibull$\ln\left\lbrack {- \ln\left( {1 - f} \right)} \right\rbrack = \ \beta.\ln\left( t_{d} \right) + \beta.\ln\left( t \right)$-36.377.2433.338091.6796.678Korsmeyer- Peppas$\ln\left( f \right) = \ln\left( K \right) + n.\text{ln}\left( t \right)$-30.2410.2818.335085959Second degree polynomial$f = a.t^{2} + b.t + c$-29.0914.5038.0760.8075.2783.90

3. Results and discussion {#sec3}
=========================

More than 93 percent of referred journals are indexed at ISI, and it can be inferred that 100 percent of datasets are extracted from authentic sources. [Table 1](#tbl1){ref-type="table"} gives a clear image of investigated nanoparticles contents including drug, polymer and surface modifications and also nanoparticles characteristics including shape and size. Lactide/glycolide ratio in PLGA is 50:50 in more than 83% of data sets and in almost all of the cases, lactide is a mixture of L and D stereoisomers. Many articles did not mention PLGA molecular weight or only provided inherent viscosity of the polymer, but [Table 1](#tbl1){ref-type="table"} reveals that more than 50 percent of all the data sets are associated with PLGA with a molecular weight less than 40 kDa. Variety of drugs, nanoparticles spherical shapes and their size that is between 100 and 200 nm in most cases are also noticeable in further interpretations.

Considering the fact that release phenomenon takes place in the context of time and release medium, these two factors are demonstrated in [Table 2](#tbl2){ref-type="table"}. In article selection, it was tried to choose those similar in release medium conditions (composition, pH and temperature) that affect drug release, although the time for release tests ranged from a few minutes to 30 days; hence those studied during a short time may depict only a snapshot of a dynamic reality.

Also, Tables [2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"} summarise the results from fitting the models on 60 data. To support the data in Tables [2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}, and illustrate the overall superiority of the Weibull model in the 60 data sets we studied, the percent of data sets that present higher R^2^, lower OE, and lower AIC for the Weibull model are brought in [Table 4](#tbl4){ref-type="table"}. Obviously, the Weibull model, an empirical model describing both immediate and delayed releases from various DDSs, with lowest AIC and mean OE as well as highest NE 5, 10, 15 and 20% in the most cases best portrays drug release behavior of PLGA-based nanoparticles. AIC that is now a standard measure of conformity of model and data based on the maximum probability shows the best fit model when comparing a group of models and the model with the lowest AIC would be the best-fitted one \[[@bib61]\]. Nevertheless, minor deviations that are observable in the [Table 4](#tbl4){ref-type="table"} imply that the Weibull model might not always be the perfect drug release model and all of the parameters that affect the release phenomenon must be figured out and be controlled.Table 4Comparing all of the models with the Weibull model (% of data sets).Table 4Comparing the modelsPossible conditionsR^2^OEAICWeibull vs. Zero orderWeibull is better85%91.67%83.33%Both models are equal0%0%0%Zero order is better15%8.33%16.67%Weibull vs. First orderWeibull is better70%96.67%83.33%Both models are equal5%0%0%First order is better25%3.33%16.67%Weibull vs. HiguchWeibull is better68.33%85%73.33%Both models are equal8.33%0%0%Higuchi is better23.33%15%26.67%Weibull vs. Hixson-CrowellWeibull is better66.67%88.33%76.67%Both models are equal13.33%0%0%Hixson-Crowell is better20%11.67%23.33%Weibull vs. Square root of massWeibull is better75%91.67%81.67%Both models are equal10%0%0%Square root of mass is better15%8.33%18.33%Weibull vs. Three-second root of massWeibull is better81.67%93.33%85%Both models are equal3.33%0%0%Three-second root of mass is better15%6.67%15%Weibull vs. Korsmeyer-PeppasWeibull is better70%78.33%68.33%Both models are equal11.67%0%0%Korsmeyer-Peppas is better18.33%21.67%31.67%Weibull vs. 2^nd^ degree polynomialWeibull is better63.33%90%75%Both models are equal16.67%0%0%2^nd^ degree polynomial is better20%10%25%

4. Discussion {#sec4}
=============

Eight drug release models as well as the second degree polynomial model were compared in this study to find out whether a nearly universal model for describing drug release from PLGA-based nanoparticles, regardless of their physicochemical properties like the polymer components ratio, the polymer\'s molecular weight, and the nanoparticles size, is achievable or not. The zero order model describes drug release from a system that liberate its content with a constant rate regardless of its concentration and the release is only a function of time. The first order model refers to a system, whom its drug release rate is only a function of the remaining drug concentration. The Higuchi model implies that the amount of drug liberated form the dosage form is a function of the square root of time. The Hixson--Crowell model describes a system that the cube root of the released amount of the incorporated drug is linearly related to the time, which is specifically a system that its surface alters over time. The Square root of mass and the Three second root of mass models are also derived from the Hixson--Crowell model, implying the linear relationship between the time and the square root or the three second root of the remained drug concentration, respectively. In the Weibull model the logarithm of the released drug and logarithm of the time would have a linear relationship. Korsmeyer-Peppas is another comprehensive semi-empirical model, that could generally describe the distinct release phenomena involving either of diffusion or swelling \[[@bib13], [@bib62], [@bib63]\].

This study provides valuable evidence for the practical use of the Weibull model in drug release phenomena from PLGA nanoparticles. Among the studied models, Weibull is regarded as a favorable model which includes parameters that are sensitive to ranges of release profile. In Weibull equation, t~d~ is a location parameter denoting the lag time before the onset of the drug release procedure, while β, a shape parameter, characterises the shape of the release curve and it can be further linked to the physiological effects. In fact, for equations with β = 1 the shape of the curve is an exponential profile, β \> 1 demonstrates a sigmoidal form and β \< 1 delineates a parabolic graph. In one hand, this implies that Weibull is a flexible model with great potential to be fitted on a variety of release patterns. Release graphs of the 60 mentioned data sets (brought in the [supplementary](#appsec1){ref-type="sec"}file) also endorse this point, as they show very different patterns PLGA nanoparticles generate including almost monophasic, biphasic, triphasic and complex multiphasic release profiles. However, we should ask where this flexibility comes from? The answer is in the mathematical equation of the Weibull model, where changes in the rate of drug concentration are tempered by calculating its natural logarithm. In other words, although Weibull does not neglect alteration in the rate of release between consecutive phases of a single release pattern, it neutralises the effect of these changes on the model by calculating their logarithm. On the other hand, β could be utilised to either predict or optimise the release conditions of a DDS in the development process and have a more desirable release profile in vivo \[[@bib62], [@bib63]\].

PLGA is a polyester that can be hydrolysed into soluble oligomers and finally, monomers in the physiological condition. In PLGA matrices, whether the mechanism of dissolution would be balk erosion or surface degradation, diffusion of oligomers or solubility of the oligomers can be rate-limiting factors for the kinetics of the phenomenon. Nevertheless, the result of a study by Körber, clearly shows that degradation controls the bulk erosion of PLGA matrices in the dissolution procedure \[[@bib64]\]. Here, a parameter that helps to translate the release mathematics to the mechanistic view is the calculated slope for Korsmeyer-Peppas model for each data set. For spherical particles, m = 0.43 reveals the Fickian diffusion and m = 0.85 denotes the polymer swelling, while any quantity between these two limitations illustrates an anomalous drug release, a combination of Fickian diffusion and swelling \[[@bib11]\]. Accordingly, the average of Korsmeyer-Peppas model slope for 60 datasets is 0.437 that confirms swelling is negligible about all these PLGA-based nanoparticles and thus, is in agreement with the previous studies emphasizing on the role of diffusion in the dissolution procedure of PLGA-based systems \[[@bib64]\].

One of the study\'s challenges was the precision of data gathering, as they were extracted from referenced articles\' release graphs. The other issue of concern with such retrospective studies is the reliability of reported data because it is not plausible for a single research team to investigate such a data mass in one lab under the same circumstance and hence must trust reliable sources.

On the other side, the present study attempts to suggest the best conventional mathematical model, describing drug release from PLGA nanoparticles mentioning different surface modifications or various incorporated drugs to investigate their likely overall effect on the mathematical model of release. Nevertheless, it has been mentioned in the literature that the loaded drug can affect the rate and mechanism of the release phenomenon for PLGA-based matrices by shifting the degradation between bulk erosion and surface degradation \[[@bib65]\]. Finally, it is necessary to keep in mind that kinetic analysis of drug release is crucial to make release phenomenon from novel DDSs predictable, especially for further pharmacokinetic-pharmacodynamic and *in vitro-in vivo* correlation studies.

Since the study of drug release kinetics provides essential data for better realising and optimising nanoparticulate DDSs, there are different methods for the determination of release kinetics from such formulations. In this study, the best fitted mathematical model (among the nine equations evaluated) illustrating drug release pattern from PLGA nanoparticles is figured out that is the Weibull model. It can also be inferred that drug release phenomenon for nanoparticles is dominantly polymer dependent rather than drug dependent; although more investigations might be necessary to evaluate release patterns of different drugs from PLGA matrices different in weight and modifications at the same condition to make a better judgment.
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The following is the supplementary data related to this article:Supplementary materialSupplementary material

[^1]: NM = Not mentioned in the source.

[^2]: "-" = Not applicable.

[^3]: EM = Electrophoretic mobility.

[^4]: Phase contrast microscope/PLGA = Poly lactide-co-glycolic acid; PCL = Poly (ε-caprolactone); PEI = Polyethylenimin.
